Cytology cell blocks are suitable for immunohistochemical testing for PD-L1 in lung cancer-Reference-Cited by-同舟云学术

Cytology cell blocks are suitable for immunohistochemical testing for PD-L1 in lung cancer

Published:2018-06 Issue:6 Volume:29 Page:1417-1422
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Wang H.,Agulnik J.,Kasymjanova G.,Wang A.,Jiménez P.,Cohen V.,Small D.,Pepe C.,Sakr L.,Fiset P.O.,Auger M.,Camilleri-Broet S.,Alam El Din M.,Chong G.,van Kempen L.^ORCID,Spatz A.

Funder

Jewish General Hospital Foundation

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/29/6/1417/25056900/mdy126.pdf

Reference27 articles.

1. NCCN Guidelines for Non-Small Cell Lung Cancer. Version 9.2017. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.

2. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer;Reck;N Engl J Med,2016

3. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study;Langer;Lancet Oncol,2016

4. Pembrolizumab versus docetaxel for previously treated, PD-L1- positive, advanced non-small cell lung cancer (KEYNOTE-010): a randomized controlled trial;Herbst;Lancet,2016

5. PD-1 blockade induces responses by inhibiting adaptive immune resistance;Tumeh;Nature,2014

Cited by 97 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current status and progress of PD-L1 detection: guiding immunotherapy for non-small cell lung cancer;Clinical and Experimental Medicine;2024-07-18

2. Exploratory pilot study to characterize the immune landscapes of malignant pleural effusions and their corresponding primary tumors from patients with breast carcinoma and lung adenocarcinoma;Journal of the American Society of Cytopathology;2024-05

3. Endobronchial Ultrasound Guided Transbronchial Needle Aspiration and PD-L1 Yields;Lung;2024-04-18

4. Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies: Guideline From the College of American Pathologists, Association for Molecular Pathology, International Association for the Study of Lung Cancer, Pulmonary Pathology Society, and LUNGevity Foundation;Archives of Pathology & Laboratory Medicine;2024-04-16

5. Anti-metabolic agent pegaspargase plus PD-1 antibody sintilimab for first-line treatment in advanced natural killer T cell lymphoma;Signal Transduction and Targeted Therapy;2024-03-06